This is just to let you know that I have posted my Celgene (CELG) Third Quarter 2009 analyst conference summary.
Celgene is doing well marketing its current drugs Revlimid, Thalomid and Vidaza. Since Revlimid and Vidaza are still in their global launch period, revenues are almost certain to continue to ramp. Celgene also has a variety of therapies in various stages of development. While some may not make it to market, there are enough good candidates to make it likely growth will continue well into the coming decade.
See also www.celgene.com and my main Celgene page with links to summaries of prior analyst conferences.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment